| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 45629.76 | 532958 |
| Intrinsic value (DCF) | 9815.03 | 114562 |
| Graham-Dodd Method | 3.06 | -64 |
| Graham Formula | 23444.97 | 273790 |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.